Mad Hedge Biotech and Healthcare Letter
July 25, 2024
Fiat Lux
Featured Trade:
(REVERSING THE FOG)
(SAVA), (ESALF), (BIIB), (LLY), (RHHBY), (ACIU), (AVXL), (ATHA)
Close your eyes and think back to your favorite childhood memory. Maybe it's the smell of your grandma's apple pie wafting through the kitchen, or the sound of your grandpa's belly laugh as he tickled you mercilessly.
Now imagine those memories being ripped away, one by one, until all that's left is a hollow shell of the person you once knew and loved.
That's the heartbreaking reality of Alzheimer's disease, and it's a fate that Rick Barry, the newly minted executive chairman of Cassava Sciences (SAVA), is determined to change.
You see, Barry isn't just some suit looking to make a quick buck. No, sir. This man's got skin in the game, and a personal connection to the fight against Alzheimer's that'll tug at your heartstrings.
His decision to join Cassava's board back in June 2021 was driven by a gut-wrenching story about his buddy's father, Buddy. This once-vibrant Navy fighter pilot and commercial airline captain was reduced to a shell of his former self by the cruel hand of Alzheimer's.
And folks, this ain't an isolated case. We're talking about 6.9 million Americans aged 65 and older living with this wretched disease in 2024, with that number set to double in the next 30 years.
Globally, over 55 million people are grappling with dementia, and Alzheimer's is the big, bad culprit in 60-70% of those cases.
While the situation is admittedly grim, Cassava Sciences offers a glimmer of hope: simufilam.
This experimental drug is Cassava's secret weapon, designed to whip a rogue protein called filamin A back into shape.
When filamin A goes off the rails in Alzheimer's patients, it wreaks havoc on brain function. But simufilam, like a disciplined drill sergeant, could get this unruly protein back in line, normalize cellular processes, reduce inflammation, and give synaptic function a much-needed boost.
Now, I know you're probably skeptical, but the Phase 2 trial results were nothing to sneeze at. A whopping 47% of patients saw their cognitive function improve, and the biomarkers of neurodegeneration and inflammation took a nosedive.
But the real moment of truth lies ahead in the Phase 3 trials, RETHINK-ALZ and REFOCUS-ALZ. These trials are the big leagues, with nearly 2,000 participants and top-line results expected by the end of 2024.
If simufilam can prove its mettle, it could be a game-changer for millions of Alzheimer's patients who are desperate for a breakthrough.
Of course, Cassava Sciences isn't the only horse in this race. The heavyweight contenders like Eisai (ESALF), Biogen (BIIB), Eli Lilly (LLY), Roche (RHHBY), and AbbVie (ABBV) are all jockeying for position, while smaller outfits like AC Immune (ACIU), Anavex (AVXL), and Athira Pharma (ATHA) are making some intriguing moves of their own.
But what really sets Cassava apart is the fire in their belly. When Barry says, "If you create great benefit for your patients, you'll create great value for your shareholders," you can tell he means business. This isn't just about lining pockets – it's about making a real difference in people's lives.
And let me tell you, the impact of Alzheimer's is staggering. Over 11 million Americans are providing unpaid care for their loved ones with Alzheimer's or other forms of dementia.
In 2023 alone, these unsung heroes clocked in a mind-boggling 18.4 billion hours of care, valued at a cool $350 billion.
And to make things worse, 70% of these caregivers are stressed to the max trying to coordinate care, while 66% are struggling to find resources and support. On top of that, 74% are also worried sick about their own health.
Financially, Alzheimer's is a beast that just keeps growing. In 2023, it drained $345 billion from the nation's coffers.
Fast forward to 2024, and that price tag is expected to hit $360 billion. And brace yourselves, because by 2050, we could be staring down the barrel of a $1 trillion problem.
So, is Cassava Sciences stock a slam-dunk investment? Well, that depends on your appetite for risk.
In the biotech world, the stakes are high, and the outcomes are never guaranteed. Simufilam's fate rests squarely on the results of those pivotal Phase 3 trials.
But one thing I can say with certainty is that Cassava Sciences has got guts. They're the underdog taking on Alzheimer's, armed with a potentially groundbreaking treatment and a whole lot of heart.
In a world where roughly 1 in 9 people over 65 are living with Alzheimer's, the impact of a successful therapy would be nothing short of seismic.
As investors, it's easy to get caught up in the cold, hard numbers. But sometimes, it pays to step back and consider the human element.
Behind every stock symbol, there are countless families praying for a miracle, tireless researchers burning the midnight oil, and brave souls like Rick Barry putting their money where their mouth is.
So, while I can't tell you to go all-in on Cassava Sciences just yet, I can tell you this: they're fighting the good fight. And in a world that often seems like it's gone completely off the rails, that's something worth getting behind. I suggest you buy the dip.
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
Global Market Comments
July 25, 2024
Fiat Lux
Featured Trade:
(AUGUST 5 VILNIUS LITHUANIA STRATEGY LUNCHEON)
(A NOTE ON OPTIONS ASSIGNED OR CALLED AWAY)
(TLT), (TSLA)
Come join me for lunch for the Mad Hedge Fund Trader’s Global Strategy Update, which I will be conducting in Vilnius, Lithuania at 12:00 PM on Monday, August 5, 2024. A three-course lunch is included.
I’ll be giving you my up-to-date view on stocks, bonds, currencies commodities, precious metals, and real estate.
And to keep you in suspense, I’ll be throwing a few surprises out there too. Enough charts, tables, graphs, and statistics will be thrown at you to keep your ears ringing for a week. Tickets are available for $197.
I’ll be arriving early and leaving late in case anyone wants to have a one-on-one discussion, or just sit around and chew the fat about the financial markets.
The lunch location will be emailed to you prior to the event.
I look forward to meeting you, and thank you for supporting my research.
To purchase tickets for this luncheon, please click here.
With the heightened volatility this week, I am seeing an increasing number of options positions assigned or called away.
I know all of this may sound confusing at first. But once you get the hang of it, this is the greatest way to make money since sliced bread.
I still have five positions left in my model trading portfolio that are deep in-the-money, and about to expire in 11 trading days. These are:
(GLD) 8/$210-$215 calls spread 10.00%
(BRK/B) 8/$405-$415 call spread 10.00%
(DE) 8/$330-$340 call spread 10.00%
(IBKR) 8/$110-$115 call spread 10.00%
(SLV) 8/$23-$25 call spread 10.00%
That opens up a set of risks unique to these positions.
I call it the “Screw up risk.”
As long as the markets maintain current levels, this position will expire at its maximum profit value.
With the August 16 options expirations upon us, there is a heightened probability that your short position in the options may get called away.
Although the return for those calling away your options is very small, this is how to handle these events.
If exercised, brokers are required by law to email you immediately and I know all of this may sound confusing at first. But once you get the hang of it, this is the greatest way to make money since sliced bread.
If it happens, there is only one thing to do: fall down on your knees and thank your lucky stars. You have just made the maximum possible profit for your position instantly.
Most of you have short-option positions, although you may not realize it. For when you buy an in-the-money vertical option spread, it contains two elements: a long option and a short option.
The short options can get “assigned,” or “called away” at any time, as it is owned by a third party, the one you initially sold the put option to when you initiated the position.
You have to be careful here because the inexperienced can blow their newfound windfall if they take the wrong action, so here’s how to handle it correctly.
Let’s say you get an email from your broker telling you that your call options have been assigned away.
I’ll use the example of the Berkshire Hathaway (BRK/B) August 2024 $405-$415 in-the-money vertical Bull Call spread since so many of you have these.
For what the broker had done in effect is allow you to get out of your call spread position at the maximum profit point 11 days before the August 16 expiration date.
In other words, what you bought for $8.70 on July 12 is now worth $10.00, giving you a near-instant profit of $1,300 or 14.94% in only 11 trading days.
All have to do is call your broker and instruct them to “exercise your long position in your (BRK/B) August 16 $405 calls to close out your short position in the (BRK/B) August $410 calls.”
You must do this in person. Brokers are not allowed to exercise options automatically, on their own, without your expressed permission.
You also must do this the same day that you receive the exercise notice.
This is a perfectly hedged position. The name, the ticker symbol, the number of shares, and the number of contracts are all identical, so you have no exposure at all.
Call options are a right to buy shares at a fixed price before a fixed date, and one option contract is exercisable into 100 shares.
Short positions usually only get called away for dividend-paying stocks or interest-paying ETFs like the (BRK/B). There are strategies out here that try to capture dividends the day before they are payable. Exercising an option is one way to do that.
Weird stuff like this happens in the run-up to options expirations like we have coming.
A call owner may need to sell a long (BRK/B) position after the close, and exercising his long (BRK/B) call, which you are short, is the only way to execute it.
Adequate shares may not be available in the market, or maybe a limit order didn’t get done by the market close.
There are thousands of algorithms out there that may arrive at some twisted logic that the puts need to be exercised.
Many require a rebalancing of hedges at the close every day which can be achieved through option exercises.
And yes, options even get exercised by accident. There are still a few humans left in this market to blow it by writing shoddy algorithms.
And here’s another possible outcome in this process.
Your broker will call you to notify you of an option called away, and then give you the wrong advice on what to do about it.
There is a further annoying complication that leads to a lot of confusion. Lately brokers have resorted to sending you warnings that exercises MIGHT happen to help mitigate their own legal liability.
They do this even when such an exercise has zero probability of happening, such as with a short call option in a LEAPS that has a year or more left until expiration. Just ignore these, or call your broker and ask them to explain.
This generates tons of commissions for the broker but is a terrible thing for the trader to do from a risk point of view, such as generating a loss by the time everything is closed and netted out.
There may not even be an evil motive behind the bad advice. Brokers are not investing a lot in training staff these days. In fact, I think I’m the last one they really did train.
Avarice could have been an explanation here but I think stupidity and poor training and low wages are much more likely.
Brokers have so many ways to steal money legally that they don’t need to resort to the illegal kind.
This exercise process is now fully automated at most brokers but it never hurts to follow up with a phone call if you get an exercise notice. Mistakes do happen.
Some may also send you a link to a video of what to do about all this.
If any of you are the slightest bit worried or confused by all of this, come out of your position RIGHT NOW at a small profit! You should never be worried or confused about any position tying up YOUR money.
Professionals do these things all day long and exercises become second nature, just another cost of doing business.
If you do this long enough, eventually you get hit. I bet you don’t.
Calling All Options!
Artificial intelligence (AI) is rapidly transforming various sectors, and healthcare is no exception. A notable trend is the increasing acceptance of AI-powered medical diagnoses among Americans. This article delves into the factors driving this trend, the benefits and potential risks, and the evolving landscape of AI in healthcare.
Factors Driving the Acceptance of AI in Medical Diagnoses
Several factors contribute to the growing acceptance of AI in medical diagnoses among Americans:
Improved Accuracy and Efficiency: AI algorithms have demonstrated remarkable accuracy in diagnosing various medical conditions, often surpassing human capabilities. For instance, a study published in Nature Medicine in 2020 showed that an AI model could detect breast cancer from mammograms with greater accuracy than radiologists. This heightened accuracy translates to earlier detection and improved treatment outcomes, fostering trust in AI among patients and healthcare providers alike.
Addressing Physician Shortages: The United States faces a significant shortage of physicians, particularly in rural and underserved areas. AI-powered diagnostic tools can help bridge this gap by augmenting the capabilities of existing healthcare professionals and enabling remote consultations. This accessibility and convenience resonate with patients who may otherwise face challenges in receiving timely diagnoses.
Rising Healthcare Costs: Healthcare costs in the United States continue to escalate, burdening patients and the healthcare system. AI can streamline diagnostic processes, reduce the need for unnecessary tests, and optimize treatment plans, potentially leading to cost savings. This financial aspect appeals to both patients and healthcare payers, further fueling the adoption of AI.
Data-Driven Decision Making: AI thrives on data, and the healthcare industry is rich in patient records, medical images, and research findings. By analyzing vast amounts of data, AI algorithms can identify patterns, correlations, and subtle anomalies that may elude human observation. This data-driven approach instills confidence in the diagnostic accuracy of AI, encouraging its acceptance.
Technological Advancements: Advances in machine learning, deep learning, and natural language processing have significantly enhanced the capabilities of AI in healthcare. AI models can now interpret complex medical images, analyze unstructured clinical notes, and even engage in conversations with patients. These advancements showcase the evolving potential of AI, bolstering its credibility and acceptance.
Benefits of AI-Powered Medical Diagnoses
The integration of AI in medical diagnoses offers a multitude of benefits:
- Enhanced Accuracy: AI algorithms can consistently outperform humans in diagnosing certain conditions, leading to earlier detection and improved treatment outcomes.
- Increased Efficiency: AI can automate repetitive tasks, freeing up healthcare professionals to focus on complex cases and patient care.
- Improved Access to Care: AI-powered tools can facilitate remote consultations and diagnoses, reaching patients in underserved areas.
- Reduced Healthcare Costs: AI can optimize diagnostic processes and treatment plans, potentially leading to cost savings.
- Personalized Medicine: AI can analyze individual patient data to tailor treatment plans and interventions.
- Accelerated Research and Drug Development: AI can analyze large datasets to identify potential drug targets and expedite clinical trials.
Potential Risks and Challenges
While AI holds immense promise in medical diagnoses, it also poses certain risks and challenges:
- Algorithm Bias: AI algorithms are trained on historical data, which may contain biases reflecting societal inequities. These biases can lead to inaccurate or discriminatory diagnoses for certain populations.
- Data Privacy and Security: The healthcare industry handles sensitive patient data, raising concerns about the privacy and security of this information when used by AI systems.
- Overreliance on Technology: Overreliance on AI can lead to complacency among healthcare professionals, potentially hindering their clinical judgment and decision-making skills.
- Lack of Transparency: Some AI algorithms are "black boxes," meaning their decision-making processes are not easily interpretable. This lack of transparency can raise concerns about accountability and trust.
- Regulatory and Ethical Considerations: The rapid development of AI in healthcare necessitates robust regulatory frameworks and ethical guidelines to ensure patient safety, equity, and responsible use of technology.
The Evolving Landscape of AI in Healthcare
The adoption of AI in healthcare is a dynamic and evolving landscape. Research and development are ongoing, leading to continuous improvements in AI algorithms and their applications. Collaborative efforts between healthcare providers, technology companies, and regulatory bodies are crucial to harnessing the full potential of AI while mitigating its risks.
Public Perception and Acceptance
Public perception and acceptance of AI in medical diagnoses are also evolving. Several surveys and studies have indicated a growing openness to AI among Americans. For example, a 2023 survey by Pew Research Center found that a majority of Americans (55%) were comfortable with doctors using AI to diagnose diseases and recommend treatments. However, concerns about data privacy, algorithmic bias, and job displacement remain. Continued education and transparent communication about the benefits and risks of AI are essential to foster public trust and acceptance.
Conclusion
The increasing acceptance of AI-powered medical diagnoses among Americans is a testament to the transformative potential of this technology in healthcare. AI offers numerous benefits, including enhanced accuracy, efficiency, and accessibility. However, addressing the potential risks and challenges associated with AI is crucial to ensure its responsible and equitable use.
The ongoing collaboration between healthcare professionals, technology companies, and regulatory bodies will shape the future of AI in medical diagnoses. Continued research, development, and education will pave the way for a healthcare system where AI and human expertise work in harmony to deliver personalized, efficient, and equitable care for all.
Mad Hedge Technology Letter
July 24, 2024
Fiat Lux
Featured Trade:
(THE FUTURE IS HERE)
(NO CODE)
The future is here.
No code or low code will bring a raft of new innovative tech companies to market, and we are in the early innings of this transformative development.
What is no code?
No-code is an approach to designing and using applications that requires zero coding or knowledge of programming languages.
This type of software hits us at a perfect time when the home office is beginning to become ubiquitous.
The self-service movement that empowers business users will support the creation, manipulation, and employment of data-driven applications.
If we turn back the pages of history, companies need an army of software programmers to develop even the measliest application.
That was then and this is now.
Fast forward to today and automated technology doesn’t only include cutting-edge industries like automotive cars, but also software on laptops that can be rejigged by individual entrepreneurs.
That’s right, one person with no coding experience will be able to design, develop, and offer a real-life application with meaningful business value without the help of expert programmers.
The research data backs up my thesis with research firms projecting a 23% increase in the global market for this type of technology.
During the pandemic, low-code/no-code tools saw steady growth due to their effectiveness in addressing some of tech’s most complicated challenges.
The essential need to digitize workflows and enhance customer and employee experiences will be a boost to the efficiency of commercial and operational teams.
No-code platforms have evolved from just facilitating mundane tasks to making it possible for a broader range of business employees to truly own their automation and build new software applications with no coding while increasing organizational capacity.
A few risks that larger companies might consider is that even for remote developers building new applications, governance is paramount.
IT staff will need to install guardrails and have those built into low-code/no-code platforms to maintain consistent levels of security across the organization.
Cybersecurity solutions need to be integrated into this workflow by training every employee at the organization on security behavior and using compartmentalization and limited access to prevent opportunities for mistakes.
Hard landings are hard to recover from and some can be crippling to the business model.
For no-code companies, harmonizing workflows is a key requirement for success.
In a low-code/no-code organization, departments should be able to work without silos and communicate freely across functions.
Elevated performance enabled by low-code/no-code tools will mean that the number of useful apps hurling toward the marketplace will be more and merrier than ever before.
Higher performance will no doubt usher in a new renaissance of efficiency and even better performance.
This also puts a 3 or even 4-day workweek squarely in play.
Many of the best tech minds in the world have supported the concept of working smarter instead of working harder.
A low code/no-code standard will allow for these achievements to take place.
The cratering of costs to start and run a tech firm is affected too.
Deploying startup capital to pay for other expenses will make it easier for successful incubation.
This will ultimately mean that this new type of tech company will need to embrace the fusion of IT and business staff, empowering them with composable applications to speed up the time to market for new solutions.
Low-code/no-code, APIs, and other tools are enabling companies to integrate new applications into their existing tech stack in a more seamless manner with a lift-and-shift approach vs. a rip-and-replace.
At the entrepreneur level, individuals will be able to harness the technology to build $100 million companies with a snap of the fingers when it wasn’t possible to do it before.
This is finally a chance for the little guy to recapture their moxie in the vast and sometimes overwhelming business world.
